DICERNA PHARMACEUTICALS, INC.

(DRNA)
Delayed Nasdaq  -  12/27 04:00:00 pm EST
38.22 USD   +0.58%
2021Dicerna Pharmaceuticals Coverage Dropped by Chardan After Novo Nordisk Closes Acquisition
MT
2021Chardan Drops Coverage on Neutral-Rated Dicerna Pharmaceuticals on Acquisition by Novo Nordisk
MT
2021DICERNA PHARMACEUTICALS, INC.(NASDAQGS : DRNA) dropped from S&P Global BMI Index
CI
SummaryQuotesChartsNewsRatingsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Chardan Downgrades Dicerna Pharmaceuticals to Neutral Rating From Buy on Proposed Acquisition by Novo Nordisk, Adjusts PT to $38.25 From $28

12/09/2021 | 10:29am EDT


© MT Newswires 2021
All news about DICERNA PHARMACEUTICALS, INC.
2021Dicerna Pharmaceuticals Coverage Dropped by Chardan After Novo Nordisk Closes Acquisiti..
MT
2021Chardan Drops Coverage on Neutral-Rated Dicerna Pharmaceuticals on Acquisition by Novo ..
MT
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P Global BMI Index
CI
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P TMI Index
CI
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P Biotechnology Select Industr..
CI
2021Novo Nordisk Completes Dicerna Pharmaceuticals Acquisition
MT
2021DICERNA PHARMACEUTICALS : Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acq..
PU
2021DICERNA PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice o..
AQ
2021Novo Nordisk Closes on $3.3 Billion Acquisition of Dicerna Pharmaceuticals
MT
2021Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
BU
More news
Analyst Recommendations on DICERNA PHARMACEUTICALS, INC.
More recommendations
Chart DICERNA PHARMACEUTICALS, INC.
Duration : Period :
Dicerna Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Bob D. Brown President
Shreeram Aradhye Chief Medical Officer & Executive Vice President
James B. Weissman Chief Operating Officer & Executive Vice President
Jamie Haney Director
Ulrich Christian Otte Director
Sector and Competitors
1st jan.Capi. (M$)
DICERNA PHARMACEUTICALS, INC.0.00%2 986
GILEAD SCIENCES, INC.-12.33%80 075
REGENERON PHARMACEUTICALS, INC.7.98%71 235
VERTEX PHARMACEUTICALS22.20%66 136
WUXI APPTEC CO., LTD.-17.77%42 735
BIONTECH SE-36.77%39 612